

About Us

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX™ system, is intended to provide long-lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options.

Contact Us

Medovex

3060 Royal Boulevard South Suite 150 Alpharetta, GA 30022

001 404 260 7423

medovex.com

- 1. Laplante B L, Ketchum J M, Saullo T R and DePalma M J. Multivariable Analysis of the Relationship Between Pain Referral Patterns and the Source of Chronic Low Back Pain. Pain Physician 2012, 15: 171-178.
- Haufe, S M, Mork A R. Endoscopic Facet Debridement for the treatment of facet arthritic pain – a novel new technique. Int J Med Sci 2010; 7(3): 120 – 123.



DenerveX[™] is currently not commercially available in the United States of America.

Medovex and DenerveX are trademarks of Medovex Corporation.

© Copyright 2017 Medovex Inc. All rights reserved.









BETTER LIVING THROUGH BETTER MEDICINE

Introducing the DenerveX™ System

A procedural approach designed for the long-lasting relief of facet joint pain.

Approximately 31% of the chronic low back pain patients report is attributed to the facet joint.¹ DenerveX™ is a new treatment option for facet joint pain.

The DenerveX™ treatment uses
Rotacapsulation™, a combination of high heat
and rotational capsular tissue shaving, in a
minimally invasive posterior procedure for the
treatment of Facet Joint Syndrome.




LONG-LASTING PAIN RELIEF AND IMPROVED MOBILITY²

The DenerveX[™] design is based on a manual procedure with precision and reproducibility built-in.²

▶ The patient pain score, as measured by the VAS pain scale, at 3 years follow up was reduced 75% to 100% in more than 50% of patients treated for cervical, thoracic, and/or lumbar facet joint pain.


Percent of patients experiencing a ≥ 50% improvement in pain at 3-year follow up¹



The majority of patients achieved a 75% to 100% improvement (VAS pain score) at a minimum 3-year follow up.

➤ The patient evaluated disability score, as measured by the Oswestry Disability Index, at 3 years follow up was improved 75% to 100% in more than 50% of patients treated for facet joint pain.

Percent of patients experiencing a ≥ 50% improvement in mobility at 3-year follow up¹



Mobility also improved. Most patients experienced a 75% to 100% improvement in the Oswestry Disability Index at long term follow up.






EASY-TO-USE

The physician designed and tested DenerveX™ system incorporates procedural simplicity, including:

- Minimally invasive procedure
- Three Effects, based on patients BMI, designed to deliver precise therapy for each patient
- Automatic control of therapy time
- ▶ All inclusive, ready-to-use, single use device kit

DenerveX[™] Kit





INNOVATIVE TREATMENT FOR FACET JOINT SYNDROME

The DenerveX[™] system is exclusively designed as a system to treat facet joints. It uses Rotacapsulation[™] to deliver high heat and capsular tissue shaving in a posterior capsulectomy procedure that:

- ▶ Treats the posterior synovial capsule
- ▶ Removes the facet joint nerve receptors
- ▶ Terminates the nerve

